(NYSEMKT: NRXS) Neuraxis's forecast annual revenue growth rate of 144.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 51.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.83%.
Neuraxis's revenue in 2026 is $3,569,282.On average, 4 Wall Street analysts forecast NRXS's revenue for 2026 to be $108,978,791, with the lowest NRXS revenue forecast at $98,674,976, and the highest NRXS revenue forecast at $118,644,912. On average, 3 Wall Street analysts forecast NRXS's revenue for 2027 to be $235,074,671, with the lowest NRXS revenue forecast at $225,856,056, and the highest NRXS revenue forecast at $241,988,632.
In 2028, NRXS is forecast to generate $373,152,511 in revenue, with the lowest revenue forecast at $358,519,079 and the highest revenue forecast at $384,127,585.